疏肝健脾方药对NAFLD大鼠肝细胞SREBP-1c、SCD-1 mRNA及蛋白表达的影响  

Effects of Soothing Liver and Invigorating Spleen Recipes on SREBP-1c,SCD-1 mRNA and Proteins Expression in Hepatocytes of NAFLD Rats

作　　者：徐拥建[1] 杨钦河[1] 韩莉[2] 张玉佩[1] 刘益臻[1] 金玲[2] 闫海震[1] 

机构地区：[1]暨南大学,广东广州510632 [2]暨南大学附属第一医院,广东广州510632

出　　处：《中药材》2014年第1期80-86,共7页Journal of Chinese Medicinal Materials

基　　金：国家自然科学基金(81173216)

摘　　要：目的:观察疏肝健脾方药对非酒精性脂肪性肝病(NAFLD)大鼠肝细胞SREBP-1c、SCD-1 mRNA及蛋白表达的影响,探讨其防治NAFLD的可能机制。方法:雄性SD大鼠75只随机分为正常对照组、模型组、疏肝组(柴胡疏肝散9.6 g/kg)、健脾组(参苓白术散30 g/kg)、合方组(柴胡疏肝散和参苓白术散合方39.6 g/kg),每组15只。采用高脂饲料喂养复制大鼠NAFLD模型。8 w后每组随机选取9只检测肝功及肝组织TC、TG,观察肝组织病理形态改变;同时每组取6只采用离体循环灌注Ⅳ型胶原酶法提取肝细胞,Q-PCR及Western Blot法检测肝细胞SREBP-1c、SCD-1 mRNA及蛋白表达。结果:与模型组比较,各药物干预组肝细胞SREBP-1c、SCD-1 mRNA及蛋白表达水平均有不同程度的下调(P<0.05或P<0.01),同时肝脂及病理学改变也较模型组有不同程度改善,以疏肝组作用最为显著(P<0.05)。各药物干预组组间比较,疏肝组大鼠肝细胞SREBP-1c、SCD-1 mRNA表达水平显著低于健脾组(P<0.05),而蛋白表达比较无统计学意义。结论:疏肝健脾方药可能通过抑制肝细胞SREBP-1c/SCD-1信号通路的激活,进而下调肝脏TC、TG合成,发挥防治NAFLD的作用。SREBP-1c、SCD-1 mRNA及蛋白可能是疏肝健脾方药抗NAFLD的有效作用靶点。Objective：To observe the effects of soothing liver and invigorating spleen recipes on the expression levels of SREBP-1c,SCD-1 mRNA and proteins in hepatocytes of NAFLD rats,and to explore its possible mechanisms of prevention and treatment of NAFLD.Methods：75 SD male rats were randomly divided into 5 groups：normal group,model group,soothing liver group（ administrated with 9.6 g/kg）,invigorating spleen group（ administrated with 30 g/kg） and integrated group（ administrated with 39.6 g/kg）.The rats of NASH model were induced by feeding a high-fat diet.After treatment for 8 weeks,9 rats were randomly taken to detect liver function,TC,TG and pathological changes in liver tissue.The other 6 rats of each group were taken respectively and collagenase（ Type Ⅳ） was perfused to digest liver tissue with the circulation in vitro to separate hepatocytes.Real-time Q-PCR and Western Blot were used to detect the expression levels of SREBP-1c,SCD-1 mRNA and proteins.Results：Compared with the model group,the different decrease levels of SREBP-1c,SCD-1 genes and proteins were found in all drug therapy groups（ P 0.05 or P 0.01）,as well different degrees that liver lipid and pathological changes became better,especially that of in soothing liver group.Comparison between the all drug therapy groups,the hepatocytes expression levels of SREBP-1c and SCD-1 mRNA in soothing liver group were lower than that of in invigorating spleen group（ P 0.05）,but expression levels of the proteins had no statistical significances.Conclusion：Soothing liver and invigorating spleen recipes prevent and treat NAFLD,its mechanism may be related to inhibiting the activation of SREBP-1c/SCD-1 signal pathway in hepatocytes to down-regulate TC and TG synthesis and reduce hepatic lipid deposition.SREBP-1c,SCD-1 mRNA and proteins may be the effective targets.

关 键 词：非酒精性脂肪性肝病 疏肝健脾方药 固醇调节元件结合蛋白-1C 硬脂酰辅酶A去饱和酶-1 肝细胞 

分 类 号：R285.5[医药卫生—中药学]